Moonlight Therapeutics

Eliminating Childhood Allergies

Moonlight Therapeutics is active in the therapeutics space based in United States, founded in 2021.

Profile

Moonlight Therapeutics is addressing a life-threatening gap in food allergy care: the lack of safe, practical options that protect patients from accidental exposure to allergens. Current treatments either require daily ingestion with difficult side effects or strict, unrealistic avoidance, leaving millions vulnerable to anaphylaxis. Moonlight’s solution is MOON101, a first-in-class, 5-minute, at-home microneedle-based desensitization therapy for peanut allergy. The proprietary skin-stamp delivers allergenic proteins directly to immune cells in the skin – the site where allergic responses can be retrained – enabling precise, localized dosing without gastrointestinal risk. This approach has been scientifically validated across multiple published animal studies and is backed by issued U.S. and European patents. Moonlight aims to redefine food allergy treatment by offering a safe, convenient therapy that can meaningfully improve the quality of life for patients and families.

The company sits in the therapeutics segment, where it competes on its core product or service.

The business is associated with United States.

Its current recorded stage is SOSV portfolio company.

Recorded headcount: 2-10 employees.

Website: moonlighttx.com